Particular focus was on IcoSema, a new drug by Novo Nordisk that combines once-weekly insulin icodec (approved in Europe and other countries, but not yet the U.S.) and semaglutide, a GLP-1 agonist
Frogs Skin In Your Eyes (00:32:00) Blue-Yellow Light, Sunlight
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Doug Long, IQVIAs vice president of industry relations, caught up with Pharma Commerce at the Asembia AXS25 Summit 5 to discuss exactly that
Read the full article to learn more about semaglutide and its implications for drug testing
These drugs, known as glucagon-like peptide-1 receptor agonists or GLP-1 medications, have gained attention for their role in helping people manage type 2 diabetes, and more recently, for their weight loss benefits